Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
On April 18, 2012, the Administrators of the GlaxoSmithKline Performance Share Plan notified the Company of an increase in notional interests in Ordinary Shares for a connected person. This increase resulted from the notional re-investment of the dividend paid to shareholders on April 12, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- Transaction Date: April 18, 2012.
- Share Price: 1420 pence per Ordinary Share.
- Parties Involved: Mr. P C Thomson (Director/PDMR) and Mrs. K Thomson (Connected Person).
- Transaction Volume: 75.461 Ordinary Shares (notional interest increase).
- Regulatory Basis: Notification made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).